UCLA Health Jonsson Comprehensive Cancer Center | Strategic Alliance Partners

January 31, 2022

Sara A. Hurvitz, MD, discusses progress made in 2021 with antibody-drug conjugates in HER2-positive breast cancer.

January 31, 2022

Cortney Eakin, MD, discusses racial disparities and histology trends in uterine cancer.

January 30, 2022

Cortney Eakin, MD, discusses alarming trends in uterine cancer histologies in Black women and some of the potential underlying risk factors at play.

January 27, 2022

UCLA Jonsson Comprehensive Cancer Center researchers have uncovered a potential new way to target pancreatic tumors that express high intratumoral interferon signaling

January 20, 2022

Although pembrolizumab monotherapy showed noninferiority to chemotherapy for overall survival in patients with advanced gastric or gastroesophageal junction adenocarcinoma and a PD-L1 combined positive score of 1 or higher, and a clinically meaningful benefit over chemotherapy in those with a CPS of 10 or higher, pembrolizumab plus chemotherapy failed to show superiority over chemotherapy alone in either subset.

January 14, 2022

Sara A. Hurvitz, MD, discusses the clinical implications of the ongoing phase 2 SUMMIT trial in HER2-mutated breast cancer.

January 13, 2022

The addition of ADXS-503 to the treatment of patients with metastatic non–small cell lung cancer who were progressing on pembrolizumab (Keytruda) resulted in encouraging responses and durable disease control, according to findings from the phase 1/2 trial.

December 16, 2021

Preliminary research with datopotamab deruxtecan has shown a promising, unprecedented duration of response in heavily pretreated patients with non–small cell lung cancer.

December 14, 2021

Sara A. Hurvitz, MD, discusses the clinical implications of the phase 3 DESTINY-Breast03 trial in HER2-positive breast cancer.

December 01, 2021

Edward B. Garon, MD, discusses the potential impact of the ongoing, phase 3 TROPION-LUNG01 trial in non–small cell lung cancer.

November 08, 2021

The use of androgen deprivation therapy and prolongation of adjuvant ADT to at least 18 months in conjunction with definitive radiotherapy provides clinically meaningful benefit for patients with localized prostate cancer, irrespective of radiation dose.

November 02, 2021

Sanaz Memarzadeh, MD, PhD, discusses the potential for frontline combination therapy regimens in ovarian cancer.

October 28, 2021

Puja S. Venkat, MD, discusses unmet needs in ovarian cancer. 

October 28, 2021

Sara Hurvitz, MD, discusses the coopERA study and how these data, along with findings from other clinical trials, could lead to significant changes in treatment for patients with ER-positive/HER2-negative breast cancer.

October 20, 2021

Jay Moon Lee, MD, discusses the current state of molecular testing in early-stage non–small cell lung cancer.

October 12, 2021

Tiffany S. Lai, MD, discusses the role of maintenance therapy and secondary cytoreduction in ovarian cancer.

October 11, 2021

Puja S. Venkat, MD, discusses treatment considerations for patients with ovarian cancer.

October 04, 2021

Ritu Salani, MD, MBA, discusses the rationale for combinations of immunotherapy and PARP inhibitors in ovarian cancer.

September 29, 2021

Sara A. Hurvitz, MD, discusses the rationale for the phase 2 coopERA Breast Cancer trial in estrogen receptor–positive, HER2-negative breast cancer.

September 29, 2021

Updated overall survival data from the phase 3 MONALEESA-3 trial demonstrated a sustained benefit with the addition of ribociclib to fulvestrant in patients with hormone receptor–positive, HER2-negative advanced breast cancer, and provide further evidence that this is a feasible approach for frontline therapy in this population.